Mizuho lowered the firm’s price target on Sage Therapeutics to $16 from $18 and keeps a Neutral rating on the shares ahead of the Q2 report. The analyst believes Biogen and Sage will likely report above-consensus Q2 sales for Zurzuvae in post-partum depression. While encouraged by the launch progress, the firm remains cautious about forecasting higher than $300M in sales for 2030 before having better visibility on the potential magnitude of adoption. It cites pushed out launch year assumptions for dalzanemdor for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $18 from $23 at JPMorgan
- Sage Therapeutics price target lowered to $23 from $28 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Shareholders Back Governance and Incentives
- Sage Therapeutics data ‘head-scratcher and inconclusive,’ says Citi